Early data suggests AI-designed drug rentosertib could slow aging, NYT reports
coherence · x · 2026-09-07
The New York Times reports that Insilico Medicine says clinical trial data for rentosertib, its AI-generated drug candidate for chronic lung disease, hints at a second benefit: slowing aging.
- The drug's molecular structure was designed with generative AI; a prior trial showed it could help treat chronic lung disease
- New results published in Nature Biotechnology show the drug reduced biological markers of age as measured by six "aging clocks" — AI models that predict morbidity and mortality
- Reporter Cade Metz calls the trial a milestone in the broader effort to apply chatbot-era AI techniques to drug discovery; Insilico is one of many startups, tech giants, and academic labs in the space
Related event: AI-Designed IPF Drug Rentosertib Shows Biological Age Reversal in Trial(18 posts)→
More from Apps
- YC F26 startup AnyAlpha launches agentic trading platform that turns ideas into 24/7 trading agents — Scobleizer · 2026-10-27
- Anthropic Expands Claude for Nonprofits as 25,000+ Organizations Adopt Claude — claudeai · 2026-10-27
- Claude Projects now lets you drag threads into the message box or @ mention them for precise context — dfeinition · 2026-10-27
- Higgsfield launches Playable: turn a single prompt into a playable mobile game — CurieuxExplorer · 2026-10-27
- Open launches Open for Sales: one prompt to build voice, email and WhatsApp AI campaigns — ycombinator · 2026-10-27
- Rork streamlines app screenshot localization across 10+ languages — rudrank · 2026-10-27